News & Events

Learn about what's new with CMC Biologics

Catalyst Biosciences and CMC Biologics Announce Manufacturing Agreement for Catalyst's Next-Generation Factor VIIa Product CB 813d


Companies Committed to Establishing Manufacturing Capabilities for Next-Generation Factor Vlla CB 813d

Catalyst Plans to Initiate Clinical Pivotal Trial in Hemophilia A and B "Inhibitor" Patients in 2017

SOUTH SAN FRANCISCO, Calif. and BOTHELL, Wash. and COPENHAGEN, Denmark – May 24, 2016 (GLOBE NEWSWIRE) – Catalyst Biosciences, Inc. (NASDAQ:CBIO), a leading biotechnology company focused on discovering and developing novel protease therapeutics for treatments of serious medical conditions in the fields of hemostasis and anti-complement, and CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, today announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of CB 813d, Catalyst’s next-generation long-acting Factor VIIa product. Catalyst is developing CB 813d for the treatment of hemophilia A and B inhibitor patients.

View or Download as a PDF  

Follow Us
Join us on LinkedIn Follow us on Twitter